Anti-Sa antibody is an accurate diagnostic and prognostic marker in adult rheumatoid arthritis

Journal of Rheumatology

Volumn 26, Issue 1, 1999, Pages 7-13

  Hayem, Gilles ^b   Chazerain, Pascal ^b   Combe, Bernard ^b   Elias, Alida ^b   Haim, Thérèse ^b   Nicaise, Pascale ^b   Benali, Karim ^b   Eliaou, Jean François ^b   Kahn, Marcel Francis ^b   Sany, Jacques ^b   Meyer, Olivier ^a  

^a BICHAT HOSPITAL   (France)

^b NONE

Author keywords

Anti Sa; Antibodies; Autoantibodies; Diagnosis; Prognosis; Rheumatoid arthritis

Indexed keywords

ANTIPERINUCLEAR FACTOR; AUTOANTIBODY; HLA ANTIGEN CLASS 2; IMMUNOGLOBULIN G ANTIBODY; KERATIN ANTIBODY; PLACENTA EXTRACT; RA33 ANTIBODY; RHEUMATOID FACTOR; SA ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANTIBODY DETECTION; ANTIBODY SPECIFICITY; ARTICLE; CHILD; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; HELA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS;

ADULT; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; BLOTTING, WESTERN; CASE-CONTROL STUDIES; HLA ANTIGENS; HUMANS; PROGNOSIS; SENSITIVITY AND SPECIFICITY; SEROEPIDEMIOLOGIC STUDIES;

EID: 0032891502     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Weinblatt ME. Rheumatoid arthritis: treat now, not later! Ann Intern Med 1996;124:773-4.
2. Van der Heide A, Jacobs JWG, Bijlsma JWJ, et al. The effectiveness of early treatment with "second line" antirheumatic drugs. A randomized, controlled trial. Ann Intern Med 1996;124:699-707.
3. Mottonen T, Paimela L, Ahonen J, Helve T, Hannonen P, Leirisalo Repo M. Outcome in patients with early rheumatoid arthritis treated according to the "sawtooth" strategy. Arthritis Rheum 1996; 39:996-1005.
4. Pasero G, Prioli F, Marubini E, et al. Slow progression of joint damage in early rheumatoid arthritis treated with cyclosporin A. Arthritis Rheum 1996;39:1006-15.
5. Combe B, Eliaou JF, Daures JP, Meyer O, Clot J, Sany J, Prognostic factors in rheumatoid arthritis. Comparative study of two subsets of patients according to severity of articular damage. Br J Rheumatol 1995;34:529-34.
6. Cordonnier C, Meyer O, Palazzo E, et al. Diagnostic value of anti-RA33 antibody, antikeratin antibody, antiperinuclear factor and antinuclear antibody in early rheumatoid arthritis: comparison with rheumatoid factor. Br J Rheumatol 1996;35:620-4.
7. Young B, Mallya R, Leslie R, Clark C, Hamblin T. Antikeratin antibodies in rheumatoid arthritis. BMJ 1979;2:97-9.
8. Paimela L, Gripenberg M, Kurki P, Leirisalo Repo M. Antikeratin antibodies: diagnostic and prognostic markers for early rheumatoid arthritis. Ann Rheum Dis 1992;51:743-6.
9. Westgeest AAA, Boerbooms AMTH, Jongmans M, Vandenbroucke JP, Vierwinden G, Van De Putte LBA. Antiperinuclear factor: indicator of more severe disease in seronegative rheumatoid arthritis. J Rheumatol 1987;14:893-7.
10. Berthelot JM, Maugars Y, Castagne E, Audrain M, Prost A. Antiperinuclear factors are present in polyarthritis before ACR criteria for rheumatoid arthritis are fulfilled. Ann Rheum Dis 1997;56:123-5.
11. Munoz-Fernandez S, Alvarez-Doforno R, Cuesta M, Balsa A, Fontan G, Gijon-Banns J. Antiperinuclear factor: a useful test for the diagnosis of rheumatoid arthritis. Br J Rheumatol 1997;36:710-1.
12. Munoz-Fernandez S, Balsa A, Hall ND, Alvarez-Doforno R, Vicario JL, Barnes J, Maddison PJ. Antiperinuclear factor in early synovitis. Rheumatol Int 1995;15:145-9.
13. Hassfeld W, Steiner G, Hartmunth K, et al. Demonstration of a new antinuclear antibody (anti-RA 33) that is highly specific for rheumatoid arthritis. Arthritis Rheum 1989;32:1515-20.
14. Meyer O, Tauxe F, Fabregas D, et al. Anti-RA 33 antinuclear antibody in rheumatoid arthritis and mixed connective tissue disease: comparison with antikeratin and antiperinuclear antibodies. Clin Exp Rheumatol 1993;11:473-8.
15. Hassfeld W, Steiner G, Graninger W, Witzman G, Schweitzer H, Smolen J. Antibody to the nuclear antigen RA 33: a marker for early rheumatoid arthritis. Br J Rheumatol 1993;32:199-203.
16. Despres N, Boire G, Lopez Longo FJ, Menard HA. The Sa system: a novel antigen antibody system specific for rheumatoid arthritis. J Rheumatol 1994;21:1027-33.
17. Despres N, Talbot G, Plouffe B, Boire G, Menard HA. Detection and expression of a cDN A clone that encodes a polypeptide containing two inhibitory domains of human calpastatin and its recognition by rheumatoid arthritis sera. J Clin Invest 1995; 95:1891-6.
18. Mimori T, Suganuma K, Tanami Y, et al. Autoantibodies to calpastatin (an endogenous inhibitor for calcium-dependent neutral protease, calpain) in systemic rheumatic diseases. Proc Natl Acad Sci USA 1995;92:7267-71.
19. Menard HA, El-Amine M. The calpain-calpastatin system in rheumatoid arthritis. Immunol Today 1996;17:545-7.
20. Arnett F, F.dworthy S, Bloch A, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
21. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. Acta Radiol Diagn 1977;18:481-91.
22. Buyon JP, Slade SG, Chan EKL, Tan EM, Winchester R. Effective separation of the 52 kDa SSA/Ro polypeptide from the 48 kDa SSB/La polypeptide by altering conditions of polyacrylamide gel electrophoresis. J Immunol Methods 1990;129:207-10.
23. Chan KWA, Felson DT, Yood RA, Walker AM. The lag time between onset of symptoms and diagnosis of rheumatoid arthritis. Arthritis Rheum 1994;37:814-20.
24. Lopez Longo FJ, Grau R, Monteagudo I, et al. Dissociation of immune response to the degraded and nondegraded (native) Sa antigens in rheumatoid arthritis and systemic lupus erythematosus [abstract]. Br J Rheumatol 1996;35 Suppl 1:18.
25. Wolfe F, Hawley DI, Cathey MA. Clinical and health measures over time: prognosis and outcome assessment in rheumatoid arthritis. J Rheumatol 1991;18:1290-7.
26. Van De Heidje DMFM, Van Leeuwen MA, Van Riel PLCM, et al. Biannual radiographic assessments of hands and feet in a three-year prospective follow-up of patients with early rheumatoid arthritis. Arthritis Rheum 1992;35:26-34.
27. Fuchs HA, Kaye JJ, Callahan LF, Nance EP, Pincus T. Evidence of significant radiographic damage in rheumatoid arthritis within the first 2 years of disease. J Rheumatol 1989;16:585-91.
28. Mottonen TT. Prediction of erosiveness and rate of development of new erosions in early rheumatoid arthritis. Ann Rheum Dis 1988;47:648-53.
29. Plant MJ, Saklatvala J, Borg AA, Jones PW, Dawes PT. Measurement and prediction of radiological progression in early rheumatoid arthritis. J Rheumatol 1994;21:1808-13.
30. Paulus HE, Van Der Heijde DMFM, Bulpitt KJ, Gold RH. Monitoring radiographic changes in early rheumatoid arthritis. J Rheumatol 1996;23:801-5.
31. Van Zeben D, Hazes JMW, Zwinderman AH, Vandenbroucke JP, Breedveld FC. Factors predicting outcome of rheumatoid arthritis: results of a follow-up study. J Rheumatol 1993;20:1288-96.
32. Van Der Heide A, Remme CA, Hofman DM, Jacobs JWG, Bijlsma JWJ. Prediction of progression of radiologie damage in newly diagnosed rheumatoid arthritis. Arthritis Rheum 1995;38:1466-74.
33. Wolfe F. Comparative usefulness of C-reactive protein and erythrocyte sedimentation rate in patients with rheumatoid arthritis. J Rheumatol 1997;24:1477-85.
34. Van Leeuwen MA, Van Rijswijk MH, Sluiter WJ, et al. Individual relationship between progression of radiological damage and the acute phase response in early rheumatoid arthritis. Towards development of a decision support system. J Rheumatol 1997; 24:20-7.